Research programme: cancer therapeutics - Selvita

Drug Profile

Research programme: cancer therapeutics - Selvita

Alternative Names: GCN2 kinase inhibitor - Selvita; General control non-repressed kinase inhibitor - Selvita; Serine hydroxymethyltransferase 2 inhibitors - Sevita; SHMT2 inhibitors - Selvita; Stimulator of interferon genes agonist - Selvita; STING agonists - Selvita

Latest Information Update: 19 Dec 2016

Price : $50

At a glance

  • Originator Selvita
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Hydroxymethyl and formyl transferase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 12 Dec 2016 Preclinical trials in Cancer in Poland (unspecified route) before December 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top